Pictured: MTAA CEO Ian Burgess, ANU Professor Mike Calford, MTPConnect Chair Sue MacLeman and WearOptimo Founder and CEO Professor Mark Kendall in April 2018 at the launch of BioMedTech Horizons in Melbourne.
Project title: Microwearables: Leaping towards precision medicine
Microwearables (simple, wearable devices) have the opportunity to be a cornerstone of precision medicine by offering personalised diagnostics across a range of diseases.
These devices are minimally-invasive, pain-free sensors applied to the skin to access key biomarkers and biosignals – for both episodic and continuous monitoring. In doing so, Microwearables aim to leapfrog traditional diagnostics: based on lab-based assays of blood samples and histopathology – with the costs, risks and time-delays.
WearOptimo will be developed as a fit-for-purpose enterprise to rapidly compete at scale – meeting the unique opportunity at the nexus of three growing markets: IoT for medicine; personalised medicine; and wearable devices for healthcare. Led by Professor Mark Kendall and in partnership with the Australian National University (ANU), this project will take the next critical step in working to advance Microwearables into an enterprise – that is commercial, with technical proof-of-concept, and is investor ready.
BMTH Round: One
|Consortium Lead||WearOptimo Pty Ltd|
|Consortium Partners||The Australian National University, Queensland Government, Johnson & Johnson Innovation & Australian National Fabrication Facility (ANFF)|
|Funding||MTPConnect grant: $891,500 |
Industry contribution: $1,591,500
|Duration||July 2018 - October 2019|
|Outcomes||Microwearables have been validated for hydration and troponin-sensing. The company has secured $30 million to manufacture its smart sensor technology at an advanced technology facility in Brisbane – for worldwide distribution.|
|Contact||Professor Mark Kendall, Founder & CEO WearOptimo|